TP53 and B-cell chronic lymphocytic leukemia: Treatment of CLL cells with venetoclax induces the rapid onset of apoptosis in vitro and in vivo via a TP53-independent mechanism [2,3], providing the rationale for evaluating use of venetoclax as targeted therapy in CLL.